Alcon ends macular degeneration drug program
LOS ANGELES (Reuters) - Alcon Inc said on Friday that it has ended development of anecortave acetate as a treatment for lowering the risk of a sight-threatening eye disease known as age-related macular degeneration.
Alcon said the decision followed a planned interim analysis of clinical studies.
The company said it continues to study anecortave acetate to reduce intraocular pressure in patients with open-angle glaucoma.
(Reporting by Deena Beasley, editing by Richard Chang)
© Thomson Reuters 2009 All rights reserved
Healthcare Reform
Reuters provides an in-depth look at the issues facing Americans as the Obama administration wrestles with healthcare policy. Full Coverage
Bosnia mourns Srebrenica victims.
